This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Disorders of lipid metabolism
  • /
  • Fenofibrate/simvastatin fixed-dose combination in ...
Journal

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.

Read time: 1 mins
Published:16th Feb 2017
Author: Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A et al.
Availability: Free full text
Ref.:Vasc Health Risk Manag. 2017;13:29-41.
DOI:10.2147/VHRM.S95044
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy


Lipids disorder is the principal cause of atherosclerosis and may present with several forms, according to blood lipoprotein prevalence. One of the most common forms is combined dyslipidemia, characterized by high levels of triglycerides and low level of high-density lipoprotein. Single lipid-lowering drugs may have very selective effect on lipoproteins; hence, the need to use multiple therapy against dyslipidemia. However, the risk of toxicity is a concerning issue. In this review, the effect and safety of an approved combination therapy with simvastatin plus fenofibrate are described, with an analysis of pros and cons resulting from randomized multicenter trials, meta-analyses, animal models, and case reports as well.

 

Read abstract on library site

Access full article